Cardiac amyloidosis future or investigational therapies

Cardiac amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cardiac Amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiac amyloidosis future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac amyloidosis future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac amyloidosis future or investigational therapies
CDC onCardiac amyloidosis future or investigational therapies
Cardiac amyloidosis future or investigational therapies in the news
Blogs on Cardiac amyloidosis future or investigational therapies
Directions to Hospitals Treating Cardiac amyloidosis
Risk calculators and risk factors for Cardiac amyloidosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

New therapies targeting the serum amyloid protein (SAP), which is an excellent immunogen and a universal component of all amyloid deposits, using monoclonal antibodies are currently being investigated.

Future and Investigational Therapies

Possible future treatment options which are currently being investigated include:

• Anti-SAP antibody
• CPHPC

CPHPC also called R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid is a competitive inhibitor of SAP binding to amyloid fibrils.

References

Template:WikiDoc Sources